Itrazole 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and candidiasis. Itrazole 200 Capsule is administered orally and exhibits good bioavailability, with absorption enhanced when taken with food. The drug is metabolized primarily in the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Serious side effects may involve hepatotoxicity and congestive heart failure in susceptible individuals. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals and should be used with caution in those receiving medications metabolized by CYP3A4. Monitoring liver function tests during prolonged therapy is recommended. Itrazole 200 Capsule should be prescribed and used under medical supervision to ensure safe and effective treatment outcomes.